Le Lézard
Classified in: Health
Subjects: CCA, TRD, FVT

Varian U.S. Tariff Exclusion Request Granted for Radiotherapy System Components


PALO ALTO, Calif., Sept. 23, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the United States Trade Representative (USTR) has granted exclusion of components sourced from China for linear accelerators manufactured in the U.S from Section 301 tariffs. The exemption became effective on September 20, 2019.

"We are thankful for the USTR and U.S. government's continued recognition of the positive impact of Varian treatment technology in the fight against cancer by granting a tariff exclusion to these components," said Dow Wilson, president and chief executive officer, Varian. "The supply of components without disruption plays an important role in our system manufacturing process so we can continue delivering cancer fighting technology and honor our commitment to creating a world without fear of cancer."

Varian is in its quiet period but will evaluate if further comments are necessary after completing its assessment of the impact of this exclusion.  The company's fiscal year 2019 earnings conference call is scheduled for Wednesday, October 23, 2019 at 1:30pm Pacific Time.

About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 9,200 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

SOURCE Varian


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: